{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:27:14Z","timestamp":1793600834926,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,25]],"date-time":"2027-03-25T00:00:00Z","timestamp":1805932800000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ygyno.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:01:21Z","timestamp":1774461681000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The progesterone paradigm: Molecular prognostication in conservative management of endometrial cancer"],"prefix":"10.1016","volume":"208","author":[{"given":"Aparna","family":"Kailasam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"De Vitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cucinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Fought","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen E.","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Cliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Langstraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.03.004_bb0005","author":"Surveillance Epidemiology and End Results (SEER)"},{"key":"10.1016\/j.ygyno.2026.03.004_bb0010","author":"National Comprehensive Cancer Network (NCCN)"},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.004_bb0015","doi-asserted-by":"crossref","first-page":"60.e1","DOI":"10.1016\/j.ajog.2019.08.002","article-title":"Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia","volume":"222","author":"Vetter","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.004_bb0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ygyno.2011.11.043","article-title":"Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature","volume":"125","author":"Baker","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.004_bb0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/AOG.0000000000002390","article-title":"Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device","volume":"131","author":"Pal","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.03.004_bb0030","doi-asserted-by":"crossref","first-page":"191.e1","DOI":"10.1016\/j.ajog.2020.08.032","article-title":"Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer","volume":"224","author":"Westin","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.03.004_bb0035","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ygyno.2023.11.006","article-title":"Molecular subtyping in endometrial cancer: a promising strategy to guide fertility preservation","volume":"179","author":"Dagher","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.03.004_bb0040","series-title":"Levonorgestrel-releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer (LEVER)","author":"Westin","year":"2022"},{"issue":"5","key":"10.1016\/j.ygyno.2026.03.004_bb0045","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.03.004_bb0050","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/AOG.0000000000005297","article-title":"Management of endometrial intraepithelial neoplasia or atypical endometrial hyperplasia: ACOG clinical consensus no. 5","volume":"142","year":"2023","journal-title":"Obstetr. Gynecol."},{"key":"10.1016\/j.ygyno.2026.03.004_bb0055","series-title":"Female Genital Tumours","author":"World Health Organization","year":"2020"},{"issue":"7447","key":"10.1016\/j.ygyno.2026.03.004_bb0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ygyno.2026.03.004_bb0065","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2026.03.004_bb0070","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"K\u00f6bel","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.004_bb0075","doi-asserted-by":"crossref","DOI":"10.52054\/FVVO.15.1.065","article-title":"ESGO\/ESHRE\/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"15","author":"Rodolakis","year":"2023","journal-title":"Facts Views Vis. Obgyn."},{"issue":"4","key":"10.1016\/j.ygyno.2026.03.004_bb0080","doi-asserted-by":"crossref","first-page":"370.e1","DOI":"10.1016\/j.ajog.2020.10.003","article-title":"Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer","volume":"224","author":"Chung","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.004_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100024","article-title":"The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment","volume":"35","author":"De Vitis","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2026.03.004_bb0090","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/1471-0528.14491","article-title":"Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series","volume":"124","author":"Zakhour","year":"2017","journal-title":"BJOG"},{"issue":"12","key":"10.1016\/j.ygyno.2026.03.004_bb0095","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s11864-022-01031-6","article-title":"Contemporary use of hormonal therapy in endometrial cancer: a literature review","volume":"23","author":"Kailasam","year":"2022","journal-title":"Curr. Treat. Options Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826008462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826008462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:35:58Z","timestamp":1793597758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826008462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":19,"alternative-id":["S0090825826008462"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.03.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The progesterone paradigm: Molecular prognostication in conservative management of endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}